April 30, 2020 / 12:36 PM / a month ago

BRIEF-Syndax Pharmaceuticals Preliminarily Estimates That Its Cash, Cash Equivalents And Short-Term Investments As Of March 31, 2020 Were About $99 Mln

April 30 (Reuters) - Syndax Pharmaceuticals Inc:

* SYNDAX PHARMACEUTICALS - PRELIMINARILY ESTIMATES THAT ITS CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF MARCH 31, 2020 WERE ABOUT $99 MILLION

* SYNDAX PHARMACEUTICALS INC - ESTIMATES THAT ITS OPERATING EXPENSES FOR THREE MONTHS ENDED MARCH 31, 2020 WERE ABOUT $15.5 MILLION Source text: bit.ly/2ycRyIT Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below